Besides that, after two hours of post-treatment, ginsenoside F1 was found to be capable of crossing the blood-–brain barrier, with elevated levels of insulin-degrading enzyme and neprilysin proteins after eight weeks of administration of 10 mg/kg/d ginsenoside F1 and reduced Aβ plaques in mice models of Alzheimer’s disease (AD) [97]. Here, MME is linked to Alzheimer disease.